Editas Medicine, Inc. (NASDAQ:EDIT) has received an average recommendation of “Buy” from the nine brokerages that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $26.54.

A number of equities analysts recently commented on EDIT shares. Zacks Investment Research cut shares of Editas Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Cann started coverage on shares of Editas Medicine in a research report on Monday, July 17th. They issued a “market perform” rating on the stock. J P Morgan Chase & Co set a $27.00 target price on shares of Editas Medicine and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a research report on Tuesday, July 18th. Finally, SunTrust Banks, Inc. started coverage on shares of Editas Medicine in a research report on Thursday, July 13th. They issued a “hold” rating and a $17.00 target price on the stock.

COPYRIGHT VIOLATION WARNING: “Editas Medicine, Inc. (EDIT) Given Average Rating of “Buy” by Analysts” was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/editas-medicine-inc-edit-given-average-rating-of-buy-by-analysts/1532774.html.

Editas Medicine (NASDAQ:EDIT) opened at 21.26 on Thursday. The firm’s market cap is $870.09 million. Editas Medicine has a 52-week low of $12.43 and a 52-week high of $29.20. The company’s 50 day moving average price is $17.75 and its 200 day moving average price is $19.12.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Wednesday, August 9th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.01. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $2.20 million. Editas Medicine had a negative return on equity of 67.75% and a negative net margin of 2,091.36%. Editas Medicine’s revenue for the quarter was down 8.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.54) EPS. Analysts predict that Editas Medicine will post ($2.84) earnings per share for the current fiscal year.

In other Editas Medicine news, insider Katrine Bosley sold 16,666 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $20.02, for a total value of $333,653.32. Following the sale, the insider now owns 1,431,095 shares of the company’s stock, valued at approximately $28,650,521.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Boris Nikolic purchased 35,000 shares of the business’s stock in a transaction on Friday, June 2nd. The stock was purchased at an average cost of $14.07 per share, for a total transaction of $492,450.00. Following the acquisition, the director now owns 35,000 shares in the company, valued at $492,450. The disclosure for this purchase can be found here.

A number of large investors have recently made changes to their positions in EDIT. IHT Wealth Management LLC purchased a new stake in shares of Editas Medicine during the second quarter worth about $107,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Editas Medicine during the second quarter worth about $127,000. Bank of America Corp DE raised its stake in shares of Editas Medicine by 72.2% in the first quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after buying an additional 2,489 shares during the period. Legal & General Group Plc raised its stake in shares of Editas Medicine by 308.4% in the second quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after buying an additional 6,535 shares during the period. Finally, Creative Planning raised its stake in shares of Editas Medicine by 8,910.9% in the second quarter. Creative Planning now owns 9,101 shares of the company’s stock worth $153,000 after buying an additional 9,000 shares during the period. 70.17% of the stock is currently owned by institutional investors and hedge funds.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.